A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Recruiting

Phase 2

A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06833073

Conditions

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma in Situ

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

V940

BCG

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-03-26.